REFERENCES
1. Blach S, Zeuzem S, Manns M, Altraif I, Duberg AS, et al. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol 2017;2:161-76.
2. Dore GJ, Freeman AJ, Law M, Kaldor JM. Is severe liver disease a common outcome for people with chronic hepatitis C? J Gastroenterol Hepatol 2002;17:423-30.
3. Limburg W; European Monitoring Centre for Drugs and Drug Addiction. Natural history, treatment and prevention of hepatitis C in injecting drug users: an overview. Available from: http://www.emcdda.europa.eu/system/files/publications/44/EMCDDAmonograph7-en_5982.pdf [Last accessed on 12 Oct 2018] .
4. Wong RJ, Aguilar M, Cheung R, Perumpail RB, Harrison SA, et al. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology 2015;148:547-55.
5. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380:2095-128.
6. Stanaway JD, Flaxman AD, Naghavi M, Fitzmaurice C, Vos T, et al. The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013. Lancet 2016;388:1081-8.
7. de Martel C, Maucort-Boulch D, Plummer M, Franceschi S. World-wide relative contribution of hepatitis B and C viruses in hepatocellular carcinoma. Hepatology 2015;62:1190-200.
8. Okanoue T, Sakamoto S, Itoh Y, Minami M, Yasui K, et al. Side effects of high-dose interferon therapy for chronic hepatitis C. J Hepatol 1996;25:283-91.
9. WHO. Combating hepatitis B and C to reach elimination by 2030: advocacy brief. Available from: https://www.who.int/hepatitis/publications/hep-elimination-by-2030-brief/en/ [Last accessed on Oct 2018].
10. Nelson PK, Mathers BM, Cowie B, Hagan H, Des Jarlais D, et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet 2011;378:571-83.
12. Scott N, Doyle JS, Wilson DP, Wade A, Howell J, et al. Reaching hepatitis C virus elimination targets requires health system interventions to enhance the care cascade. Int J Drug Policy 2017;47:107-16.
13. Walmsley R; Internation Centre for Prison Studies. World prison population list (tenth edition). Available from: https://www.prisonstudies.org/sites/default/files/resources/downloads/wppl_10.pdf [Last accessed on 9 Oct 2018].
14. Wagner P, Rabuy B; Prison Policy Initiative. Mass incarceration: the whole pie 2016. Available from: https://www.prisonpolicy.org/reports/pie2018.html [Last accessed on 9 Oct 2018].
15. Dolan K, Wirtz AL, Moazen B, Ndeffo-Mbah M, Galvani A, et al. Global burden of HIV, viral hepatitis, and tuberculosis in prisoners and detainees. Lancet 2016;388:1089-102.
16. Murphy EL, Bryzman SM, Glynn SA, Ameti DI, Thomson RA, et al. Risk factors for hepatitis C virus infection in United States blood donors. Hepatology 2000;31:756-62.
17. Jürgens R, Nowak M, Day M. HIV and incarceration: prisons and detention. J Int AIDS Soc 2011;14:26.
18. Beckman AL, Bilinski A, Boyko R, Camp GM, Wall AT, et al. New hepatitis C drugs are very costly and unavailable to many state prisoners. Health Aff (Millwood) 2016;35:1893-901.
19. DeBeck K, Cheng T, Montaner JS, Beyrer C, Elliott R, et al. HIV and the criminalisation of drug use among people who inject drugs: a systematic review. Lancet HIV 2017;4:e357-74.
20. Larney S, Kopinski H, Beckwith CG, Zaller ND, Jarlais DD, et al. Incidence and prevalence of hepatitis C in prisons and other closed settings: results of a systematic review and meta-analysis. Hepatology 2013;58:1215-24.
21. Boonwaat L, Haber PS, Levy MH, Lloyd AR. Establishment of a successful assessment and treatment service for Australian prison inmates with chronic hepatitis C. Med J Aust 2010;192:496-500.
22. Lloyd AR, Clegg J, Lange J, Stevenson A, Post JJ, et al. Safety and effectiveness of a nurse-led outreach program for assessment and treatment of chronic hepatitis C in the custodial setting. Clin Infect Dis 2013;56:1078-84.
23. WHO. Prisons and health. Available from: https://www.euro.who.int/__data/assets/pdf_file/0005/249188/Prisons-and-Health.pdf [Last accessed on 9 Oct 2018].
24. ECDC. Technical report: surveillance and prevention of hepatitis B and C in Europe. Available from: https://ecdc.europa.eu/sites/portal/files/media/en/publications/Publications/101012_TER_HepBandC_survey.pdf [Last accessed on 9 Oct 2018].
25. Spaulding AC, Weinbaum CM, Lau DT, Sterling R, Seeff LB, et al. A framework for management of hepatitis C in prisons. Ann Intern Med 2006;144:762-9.
26. Imperial JC. Chronic hepatitis C in the state prison system: insights into the problems and possible solutions. Expert Rev Gastroenterol Hepatol 2010;4:355-64.
27. De P, Connor N, Bouchard F, Sutherland D. HIV and hepatitis C virus testing and seropositivity rates in Canadian federal penitentiaries: a critical opportunity for care and prevention. Can J Infect Dis Med Microbiol 2004;15:221-5.
28. Kirwan P, Evans B, Brant L; Sentinel Surveillance of Hepatitis Testing Study Group. Hepatitis C and B testing in English prisons is low but increasing. J Public Health (Oxf) 2011;33:197-204.
29. Rich JD, Beckwith CG, Macmadu A, Marshall BDL, Brinkley-Rubinstein L, et al. Clinical care of incarcerated people with HIV, viral hepatitis, or tuberculosis. Lancet 2016;388:1103-14.
30. Post JJ, Arain A, Lloyd AR. Enhancing assessment and treatment of hepatitis C in the custodial setting. Clin Infect Dis 2013; doi: 10.1093/cid/cit265.
31. Khaw FM, Stobbart L, Murtagh MJ. 'I just keep thinking I haven't got it because I'm not yellow': a qualitative study of the factors that influence the uptake of hepatitis C testing by prisoners. BMC Public Health 2007;7:98.
32. Hickman M, McDonald T, Judd A, Nichols T, Hope V, et al. Increasing the uptake of hepatitis C virus testing among injecting drug users in specialist drug treatment and prison settings by using dried blood spots for diagnostic testing: a cluster randomized controlled trial. J Viral Hepat 2008;15:250-4.
33. Humphreys C, Railton C, é O'Moore, Lombard M, Newton A. An audit of hepatitis C service provision in a representative sample of prisons in England. J Public Health (Oxf) 2015;37:151-6.
34. Hochstatter KR, Stockman LJ, Holzmacher R, Greer J, Seal DW, et al. The continuum of hepatitis C care for criminal justice involved adults in the DAA era: a retrospective cohort study demonstrating limited treatment uptake and inconsistent linkage to community-based care. Health Justice 2017;5:10.
35. Mina MM, Herawati L, Butler T, Lloyd A. Hepatitis C in Australian prisons: a national needs assessment. Int J Prison Health 2016;12:3-16.
36. Yap L, Carruthers S, Thompson S, Cheng W, Jones J, et al. A descriptive model of patient readiness, motivators, and hepatitis C treatment uptake among Australian prisoners. PLoS One 2014; doi: 10.1371/journal.pone.0087564.
37. James DJ, Glaze LE; Bureau of Justice Statistics Washington. Mental health problems of prison and jail inmates. Available from: https://www.bjs.gov/content/pub/pdf/mhppji.pdf [Last accessed on 9 Oct 2018].
38. Kramer JR, Kanwal F, Richardson P, Mei M, El-Serag HB. Gaps in the achievement of effectiveness of HCV treatment in national VA practice. J Hepatol 2012;56:320-5.
39. Rosenthal ES, Graham CS. Price and affordability of direct-acting antiviral regimens for hepatitis C virus in the United States. Infect Agent Cancer 2016;11:24.
40. Leclerc P, Roy é, Morissette C. Le volet montréalais du Réseau SurvUDI: Volume 2: données au 30 juin 2008: agence de la santé et des services sociaux de Montréal, direction de santé publique. Available from: http://collections.banq.qc.ca/ark:/52327/bs1983220 [Last accessed on 12 Oct 2018].
41. Razavi H, Waked I, Sarrazin C, Myers RP, Idilman R, et al. The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm. J Viral Hepat 2014;21:34-59.
42. Browne AJ, Varcoe CM, Wong ST, Smye VL, Lavoie J, et al. Closing the health equity gap: evidence-based strategies for primary health care organizations. Int J Equity Health 2012;11:59.
43. Hellard M, Sacks-Davis R, Doyle J. Hepatitis C elimination by 2030 through treatment and prevention: think global, act in local networks. J Epidemiol Community Health 2016;70:1151-4.
44. Rolls DA, Sacks-Davis R, Jenkinson R, McBryde E, Pattison P, et al. Hepatitis C transmission and treatment in contact networks of people who inject drugs. PloS One 2013; doi: 10.1371/journal.pone.0078286.
45. Olafsson S, Tyrfingsson T, Runarsdottir V, Bergmann OM, Hansdottir I, et al. Treatment as prevention for hepatitis C (TraP Hep C) - a nationwide elimination programme in Iceland using direct-acting antiviral agents. J Intern Med 2018;283:500-7.
46. Cousien A, Leclerc P, Morissette C, Bruneau J, é Roy, et al. The need for treatment scale-up to impact HCV transmission in people who inject drugs in Montréal, Canada: a modelling study. BMC Infect Dis 2017;17:162.
47. Zelenev A, Li J, Mazhnaya A, Basu S, Altice FL. Hepatitis C virus treatment as prevention in an extended network of people who inject drugs in the USA: a modelling study. Lancet Infect Dis 2018;18:215-24.
48. Martin NK, Vickerman P, Dore GJ, Grebely J, Miners A, et al. Prioritization of HCV treatment in the direct-acting antiviral era: an economic evaluation. J Hepatol 2016;65:17-25.
49. Barua S, Greenwald R, Grebely J, Dore GJ, Swan T, et al. Restrictions for medicaid reimbursement of sofosbuvir for the treatment of hepatitis C virus infection in the United States. Ann Intern Med 2015;163:215-23.
50. Stone J, Martin NK, Hickman M, Hutchinson SJ, Aspinall E, et al. Modelling the impact of incarceration and prison-based hepatitis C virus (HCV) treatment on HCV transmission among people who inject drugs in Scotland. Addiction 2017;112:1302-14.
51. Martin NK, Vickerman P, Brew IF, Williamson J, Miners A, et al. Is increased hepatitis C virus case-finding combined with current or 8-week to 12-week direct-acting antiviral therapy cost-effective in UK prisons? A prevention benefit analysis. Hepatology 2016;63:1796-808.
52. Farley JD, Wong VK, Chung HV, Lim E, Walters G, et al. Treatment of chronic hepatitis C in Canadian prison inmates. Can J Gastroenterol 2005;19:153-6.
53. Sabbatani S, Giuliani R, Manfredi R. Combined pegylated interferon and ribavirin for the management of chronic hepatitis C in a prison setting. Braz J Infect Dis 2006;10:274-8.
54. Chew KW, Allen SA, Taylor LE, Rich JD, Feller E. Treatment outcomes with pegylated interferon and ribavirin for male prisoners with chronic hepatitis C. J Clin Gastroenterol 2009;43:686-91.
55. Strock P, Mossong J, Hawotte K, Arendt V. Access to treatment of hepatitis C in prison inmates. Dig Dis Sci 2009;54:1325-30.
56. Simonović Babić J, Bojović K, Delić D, Katanić N, Mitrović N, et al. Antiviral treatment of hepatitis C in Serbian prison setting: medical treatment outcomes and patients’ adherence. Med Pregl 2016;69:85-91.
57. Maru DS, Bruce RD, Basu S, Altice FL. Clinical outcomes of hepatitis C treatment in a prison setting: feasibility and effectiveness for challenging treatment populations. Clin Infect Dis 2008;47:952-61.
58. Aspinall EJ, Mitchell W, Schofield J, Cairns A, Lamond S, et al. A matched comparison study of hepatitis C treatment outcomes in the prison and community setting, and an analysis of the impact of prison release or transfer during therapy. J Viral Hepat 2016;23:1009-16.
59. Bartlett SR, Fox P, Cabatingan H, Jaros A, Gorton C, et al. Demonstration of near-elimination of hepatitis C virus among a prison population: the Lotus Glen Correctional Centre hepatitis C treatment project. Clin Infect Dis 2018;67:460-3.
60. Blogg J, Wood J, McGrath C, Lobo C. Eradicating hepatitis C from the New South Wales prison system. Med J Aust 2018;208:276.
61. Sterling RK, Cherian R, Lewis S, Genther K, Driscoll C, et al. Treatment of HCV in the department of corrections in the era of oral medications. J Correct Health Care 2018;24:127-36.
